Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules.

Lung Cancer Clinical Trial

— SATAN  

Official title:

Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04140474
• Other study ID #: 87RI18_0030 (SATAN)
• Status: Terminated
• Phase: N/A
• Start date: January 21, 2021
• Est. completion date: July 1, 2021

Study information

• Verified date: September 2021
• Source: University Hospital, Limoges
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study protocol is to evaluate the feasibility of biopsies using the new system called Archimedes® in 12 patients with solitary pulmonary nodules (SPN) suspicious of malignancy not accessible through current bronchoscopy techniques.

Description:

Due to the improvement of screening techniques, the detection of peripheral and isolated lesions is an increasingly frequent situation. However these SPN cause difficulties in obtaining a sample. Indeed, current endoscopic techniques remain insufficient in terms of performance. Moreover, computed tomography-guided percutaneous needle biopsy despite a very good sensitivity has many limitations related to the size of the lesions, the accessibility and important complications. The Archimedes® system is an improved version of LungPoint® and combines 3D reconstruction of chest images with intraoperative radioscopy. It uses a catheter to access through the bronchial wall the pulmonary parenchyma and navigate to the SPN. All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure. Patients' participation in the study will stop once they benefit from their thoracic surgery

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: July 1, 2021
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients aged 18 to 75 years with a suspicious nodule of malignancy (primary lung tumor or metastasis of another solid tumor whose largest diameter is greater than or equal to 8 mm):

• Not associated with endobronchial tumor visible during inspection of tracheobronchial tree with soft bronchoscope

• Located in any part of the lung more than 10mm from the pleura

• For which surgical management (atypical resection, lobectomy, bilobectomy or pneumonectomy) is planned after presentation of the file at a multidisciplinary consultation meeting on thoracic oncology of the Investigating Hospital Center

• Patient able to understand the course of the study and giving informed consent

• Affiliate or beneficiary of a social security scheme

Exclusion Criteria:

• Threatening cardiac arrhythmias defined by a rhythm disorder dating discovered less than a month ago

• Myocardial infarction less than one month old

• Hypercapnic respiratory decompensation less than one month old

• coagulopathy

• Thrombocytopenia with platelet count <100,000 / mm3

• Antecedent (ATCD) of significant bleeding during previous bronchoscopy

• ATCD of pulmonary arterial hypertension (PAH) or suspicion of PAH defined by a measurement of systolic pulmonary arterial pressure greater than 50 mmHg on echocardiography (this examination is not systematic but the suspicion of PAH on the thoracic CT scan leads to other cardiac echocardiographic examinations or right heart catheterization in case of inconclusive ultrasound)

• ATCD of pneumonectomy

• Giant bubble> 5cm located near the nodule or the tunneling path

• Inability to stop anticoagulant or antiplatelet therapy before the procedure (taking acetylsalicylic acid at any dose is allowed)

• Pregnant or lactating woman

• ATCD for thoracic radiotherapy on the nodule side

• Patient under tutorship or curatorship

Related Conditions & MeSH terms

• Bronchoscopy
• Lung Cancer
• Multiple Pulmonary Nodules
• Solitary Pulmonary Nodule

Intervention

Device:
• Archimedes procedure
All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN

Locations

Country	Name	City	State
France	CHU de Limoges	Limoges

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of diagnostics obtained with the Archimedes system	It will be the biopsy yield defined as the number of patients in whom the results of nodule biopsies performed with the Archimedes® system are consistent with the surgical specimen.	Month 1
Secondary	Scheduling time of the procedure	Procedure scheduling time defined by the number of minutes elapsed between recording the patient's chest scanner on the console and when the tunneling path was examined, selected, and exported	Day 21
Secondary	Access time to the nodule	Nodule access time defined as the number of minutes elapsed between the start of navigation and the placement of the sheath within the SPN	Day 21
Secondary	Fluoroscopy time	Fluoroscopy time defined by the number of minutes the patient is exposed to ionizing radiation	Day 21
Secondary	Patient registration time	Patient recording time defined as the number of minutes required to correlate the patient's position through fluoroscopy with the navigation aid system.	Day 21
Secondary	morbi-mortality	number of hemoptysis and pneumothorax	Month 1